Compare Amgen, Inc. (AMGN) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Standard Lithium Ltd — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Standard Lithium Ltd trades at $2.4 (market cap $602.91M). The key difference: Amgen, Inc. is far larger — about 325.3× Standard Lithium Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| AMGN | SLI | |
|---|---|---|
Market Cap | $196.12B | $602.91M |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $5.65 |
52-Week Low | $271.18 | $2.29 |
Enterprise Value | $241.41B | $462.10M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Standard Lithium (SLI) trades at $2.46, down 3.15% today, showing bearish technical momentum despite unanimous analyst buy ratings. The company reported negative earnings with Q1 2026 beating expectations but Q4 2025 missing. Strong financing activities of $163.58M in 2025 support development of the South West Arkansas lithium project, with major operational milestones achieved at the demonstration plant.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include negative cash flow from operations and high capital expenditures, but the $225M DOE grant and strategic partnerships provide funding stability. Analyst consensus remains strongly bullish with 100% buy ratings, viewing current weakness as a buying opportunity for long-term lithium exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
